GlassScriptPhysician profile
Arthur Pelzer Davis
NPI 1821527391
$10,950.80
in general payments reported to CMS, 2019-2025
27 companies · $1,466 in 2025
The $1,466 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $646 · 2022: $543 · 2023: $5,543 · 2024: $2,753 · 2025: $1,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,800 · Food and Beverage: $3,958 · Travel and Lodging: $1,004 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,800.00 |
| Food and Beverage | $3,957.52 |
| Travel and Lodging | $1,003.97 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $5,438.46 | 2022-2025 | Ozempic |
| Edwards Lifesciences Corporation | $2,171.93 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Pascal |
| Astrazeneca Pharmaceuticals LP | $462.18 | 2021-2024 | Farxiga |
| Abiomed | $420.96 | 2024-2025 | Impella |
| Medtronic, INC. | $376.36 | 2023-2025 | Corevalve Evolut R, Azure Xt Dr Mri Surescan |
| Amgen INC. | $335.91 | 2021-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $297.19 | 2021-2025 | Camzyos |
| Pfizer INC. | $287.80 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $167.47 | 2024 | Xarelto |
| Abbott Laboratories | $156.15 | 2025 | Mitraclip, Amplatzer Amulet, Triclip |
| Shockwave Medical, INC | $123.02 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $121.35 | 2024-2025 | Lifevest |
| Astellas Pharma US INC | $96.40 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.09 | 2022-2023 | Jardiance |
| W. L. Gore & Associates, INC. | $60.07 | 2025 | Gore Cardioform Septal Occluder, Gore Cardioform Asd Occluder |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $50.72 | 2023-2025 | S-Icd System Magnet, Watchman Flx |
| Biotronik INC. | $40.53 | 2022-2025 | Acticor 7 Vr-T Dx |
| Philips North America LLC | $37.96 | 2025 | Mcot, Ambulatory Monitoring & Diagnostics Undivided |
| Glaxosmithkline, LLC. | $37.91 | 2025 | Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $35.66 | 2021 | |
| Bridgebio Pharma, INC. | $30.12 | 2025 | Attruby |
| Inari Medical, INC. | $29.25 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Ionis Pharmaceuticals, INC. | $26.45 | 2025 | |
| Teleflex LLC | $24.28 | 2025 | |
| Alnylam Pharmaceuticals INC. | $22.86 | 2025 | Amvuttra |
| Novartis Pharmaceuticals Corporation | $18.88 | 2025 | |
| Baxter Healthcare | $13.84 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.